Acute Agitation and Aggression Treatment Market Size, Share and Growth Outlook, 2026

Acute Agitation and Aggression Treatment Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Acute Agitation and Aggression Treatment Market size is forecast to increase from $3.21 Billion in 2026 to $4.26 Billion in 2034 at a CAGR of 3.6% between 2026 and 2034.

The Acute Agitation and Aggression Treatment market report provides detailed analysis and outlook of Acute Agitation and Aggression Treatment segments including By Product Type (Pharmaceuticals, Psychotherapeutic Devices), By Drug Class (Antipsychotics, Benzodiazepines, Others), By Route of Administration (Oral, Parenteral, Inhalation/Intranasal), By Indication (Schizophrenia, Bipolar Disorder, Dementia & Alzheimer’s Disease, Substance-Related States, Autism Spectrum Disorder ), By End User (Hospitals & Emergency Departments, Psychiatric Care Facilities, Residential Treatment Centers, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Acute Agitation and Aggression Treatment Industry Overview

Therapeutic Innovation Transforming Acute Agitation Management

The acute agitation and aggression treatment industry is experiencing significant advancement as healthcare providers seek safer and more effective therapies for managing neuropsychiatric symptoms associated with neurological and psychiatric disorders. The market has historically relied heavily on antipsychotic medications; however, growing concerns regarding adverse effects and long-term safety have accelerated interest in alternative treatment approaches. Pharmaceutical innovation is increasingly focused on therapies that target novel neurological pathways while reducing risks commonly associated with traditional interventions. These developments are expanding treatment options for patients, clinicians, and caregivers managing complex agitation-related conditions.

Auvelity Approval Introducing a New Treatment Class

A major milestone within the industry is the regulatory approval of Auvelity, a combination of dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets, for the treatment of agitation associated with dementia due to Alzheimer's disease. This approval is particularly significant because Auvelity represents the first FDA-approved therapy for this indication that is not classified as an antipsychotic medication. Unlike traditional treatments that primarily target dopamine or serotonin pathways, Auvelity acts through NMDA and sigma-1 receptor mechanisms. The introduction of a non-antipsychotic therapeutic option marks an important shift in treatment strategies for agitation associated with neurodegenerative disorders.

Clinical Trial Results Demonstrating Meaningful Symptom Improvement

The approval of Auvelity was supported by robust clinical evidence generated through the Phase III ADVANCE-1 and ACCORD-2 randomized clinical trials. Study findings demonstrated statistically significant improvements in agitation symptoms among treated patients compared with placebo, as measured using the Cohen-Mansfield Agitation Inventory (CMAI). In addition to symptom reduction, long-term clinical data showed that patients who remained on treatment experienced a longer time to relapse of agitation symptoms. These outcomes highlight the potential of novel pharmacological approaches to provide sustained management of agitation while improving overall patient stability.

Growing Clinical Support for Safer Neuropsychiatric Treatment Options

The introduction of new therapeutic approaches has received strong support from patient advocacy and healthcare organizations. The Alzheimer's Association publicly welcomed the approval of Auvelity, emphasizing the significant burden that agitation places on patients, caregivers, and healthcare systems. The organization highlighted the importance of providing clinicians with alternatives that may address some of the safety concerns associated with traditional antipsychotic therapies, including sedation and increased fall risk. As awareness of these challenges grows, the industry is increasingly focused on developing treatments that balance symptom control with improved safety and quality-of-life outcomes for patients experiencing acute agitation and aggression.

Acute Agitation and Aggression Treatment Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Acute Agitation and Aggression Treatment market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Eli Lilly and Company, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, Johnson & Johnson (Janssen), BioXcel Therapeutics, Inc., GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, AbbVie Inc.. The Acute Agitation and Aggression Treatment market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Acute Agitation and Aggression Treatment industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Acute Agitation and Aggression Treatment Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Acute Agitation and Aggression Treatment companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Acute Agitation and Aggression Treatment markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Acute Agitation and Aggression Treatment Market Competitive Benchmarking and Company Analysis

Leading companies in Acute Agitation and Aggression Treatment industry include- Eli Lilly and Company, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, Johnson & Johnson (Janssen), BioXcel Therapeutics, Inc., GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, AbbVie Inc.. The Acute Agitation and Aggression Treatment market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Acute Agitation and Aggression Treatment Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Acute Agitation and Aggression Treatment market remains one of the strongest-performing segments in the country.
The US Acute Agitation and Aggression Treatment Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Acute Agitation and Aggression Treatment market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Acute Agitation and Aggression Treatment industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Acute Agitation and Aggression Treatment markets

Canada's strong Acute Agitation and Aggression Treatment sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Acute Agitation and Aggression Treatment market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Acute Agitation and Aggression Treatment Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Acute Agitation and Aggression Treatment market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Acute Agitation and Aggression Treatment population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Acute Agitation and Aggression Treatment industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Acute Agitation and Aggression Treatment market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Acute Agitation and Aggression Treatment sales through 2034

France Acute Agitation and Aggression Treatment companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Acute Agitation and Aggression Treatment Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Acute Agitation and Aggression Treatment distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Acute Agitation and Aggression Treatment Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Acute Agitation and Aggression Treatment market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Acute Agitation and Aggression Treatment industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Acute Agitation and Aggression Treatment industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Acute Agitation and Aggression Treatment Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Acute Agitation and Aggression Treatment market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Acute Agitation and Aggression Treatment market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Acute Agitation and Aggression Treatment Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Acute Agitation and Aggression Treatment Market Segmentation

By Product Type
Pharmaceuticals
Psychotherapeutic Devices
By Drug Class
Antipsychotics
Benzodiazepines
Others
By Route of Administration
Oral
Parenteral
Inhalation/Intranasal
By Indication
Schizophrenia
Bipolar Disorder
Dementia & Alzheimer’s Disease
Substance-Related States
Autism Spectrum Disorder
By End User
Hospitals & Emergency Departments
Psychiatric Care Facilities
Residential Treatment Centers
Ambulatory Surgical Centers

Top Companies in Acute Agitation and Aggression Treatment Industry

Eli Lilly and Company
Pfizer Inc.
Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S
Johnson & Johnson (Janssen)
BioXcel Therapeutics, Inc.
GlaxoSmithKline plc (GSK)
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Company
AbbVie Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025